Company news

Emyria Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Emyria Recruits First Patient MDMA-Assisted Therapy Trial

July 9, 2023

Presentation - Pax Acquisition and Company Update

July 5, 2023

Pax Centre Acquisition to Advance Psychedelic Therapies

July 3, 2023

Emyria hails ethics approval for MDMA-assisted clinical trial

June 8, 2023

Emyria Receives Ethics Approval for MDMA-assisted Therapy

June 7, 2023

Emyria Completes $2.5m Placement

May 1, 2023

March 2023 Quarterly Activities Report and Appendix 4C

April 28, 2023

Emyria launches new high potency Ultra-Pure CBD capsule

April 24, 2023

Emyria Unveils Highest Potency CBD Capsule for FDA Pathway

April 23, 2023

Emyria to Develop Psilocybin Therapy Care Model

April 17, 2023

Emyria agrees licensing and commercialisation deal for EMD-RX5

April 4, 2023

Emyria, Aspen Sign Binding Commercial Term Sheet for EMD-RX5

April 3, 2023

Strong Recruitment for EMD-RX5 Phase 3 Trial

March 22, 2023

Emyria Grows MDMA Asset for Neuro & Mental Health Therapy

March 19, 2023

Emyria partners with PAX Centre for MDMA-assisted therapy

March 6, 2023

Half Yearly Report and Accounts

February 26, 2023

Emyria secures clinical-grade MDMA supply for Aust patients

February 12, 2023

Emyria ramps up MDMA programs following ‘incredible’ TGA decision

February 7, 2023

Emyria expands MDMA programs following landmark TGA decision

February 5, 2023

Emyria welcomes dosing of first patient in Phase 3 anxiety trial

January 31, 2023

Appendix 4C - Quarterly

January 30, 2023

First dosing commenced for pivotal EMD-RX5 Phase 3 trial

January 29, 2023

Emyria receives $2.1M R&D tax incentive refund

January 11, 2023

Emyria accepted into National Institutes of Health Program

November 27, 2022

Placement completion and secondary trading notice

November 22, 2022

Emyria completes $3m placement

October 30, 2022

Emyria and UWA expand unique MDMA-inspired analogue library

October 17, 2022

Emyria expands clinical sites for EMD-RX5 Phase 3 trial

September 25, 2022

Emyria commences US preclinical program for MDMA library

September 19, 2022

Appendix 4E and Annual Report

August 29, 2022

Positive results received for Emyrias MDMA-inspired program

August 17, 2022

Emyria receives ethics approval for EMD-RX5 Phase 3 trial

August 16, 2022

Preclinical studies initiated for MDMA-inspired analogues

August 4, 2022

Appendix 4C - Quarterly

July 27, 2022

Emyria expands drug candidate library inspired by MDMA

July 17, 2022

Emyria expands MDMA analogue program with UWA

May 31, 2022

EMD-RX5 demonstrates excellent safety and bioavailability

May 24, 2022

Further positive MDMA analogue screening results received

May 9, 2022

Broker Briefing Presentation

March 24, 2022

Emyria launches second ultra-pure CBD capsule

March 16, 2022

Recruitment commenced for EMD-RX5 Phase 1 Study

March 8, 2022

Ethics approval received for EMD-RX5 Phase 1 Study

March 3, 2022

Emyria grows its novel MDMA-analogue library

February 21, 2022

Application for quotation of securities - EMD

February 13, 2022

Phase 1 trial commences Q1, 2022 for Emyrias ultra-pure CBD

January 19, 2022

Notification regarding unquoted securities - EMD

December 30, 2021

Emyria adds wearables to psychedelic-assisted therapy trials

December 19, 2021

Pause in Trading

December 15, 2021

Positive animal data for Emyrias ultra-pure CBD capsule

December 14, 2021

Positive initial MDMA-analogue screening results

December 7, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 27 decks. Every deck is listed under its year.